SixPeaks Bio AG has made its debut with a pipeline of therapies for healthy weight loss. The company has secured $30 million in Series A financing led by founding investor Versant Ventures and a strategic collaboration with AstraZeneca that will provide additional, non-dilutive financing of up to $80 million over the next two years.
